10-KPeriod: FY2016

Medtronic plc Annual Report, Year Ended Apr 29, 2016

Filed June 28, 2016For Securities:MDT

Summary

Medtronic plc's fiscal year 2016 10-K filing highlights a transformative year primarily driven by the $50 billion acquisition of Covidien plc, which closed in January 2015. This strategic move significantly expanded Medtronic's global reach and product portfolio, integrating Covidien's operations into its existing structure. The company organized into four primary operating segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group, with combined net sales reflecting the significant impact of the Covidien integration. Despite currency headwinds and the costs associated with integration, Medtronic demonstrated revenue growth across most segments. The company continues to invest heavily in research and development to drive therapy innovation and maintain market leadership in a competitive landscape. Management's focus remains on executing its strategies for therapy innovation, globalization, and economic value creation, aiming to enhance patient outcomes and improve healthcare efficiencies.

Financial Highlights

55 data points
Beta

Revenue

$28.83B

68.3% Gross Margin

Net Income

$3.54B

12.3% Net Margin

EPS (Diluted)

$2.48

Total Assets

$99.64B

Cash & Equivalents

$2.88B

Free Cash Flow

$4.17B

Financial Statements
Beta
Revenue$28.83B
Cost of Revenue$9.14B
Gross Profit$19.69B
SG&A Expenses$9.47B
Operating Income$5.36B
Interest Expense$1.39B
Net Income$3.54B
EPS (Basic)$2.51
EPS (Diluted)$2.48
Shares Outstanding (Basic)1.41B
Shares Outstanding (Diluted)1.43B

Key Highlights

  • 1Completion of the $50 billion acquisition of Covidien plc in January 2015, significantly expanding Medtronic's scale and product offerings.
  • 2Reorganization into four operating segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.
  • 3Net sales grew to $28.83 billion in fiscal year 2016, a 42% increase compared to fiscal year 2015, largely due to the inclusion of Covidien's results.
  • 4Investment in Research and Development remained substantial, totaling $2.2 billion (7.7% of net sales) in fiscal year 2016, underscoring a commitment to innovation.
  • 5Strong performance in the Cardiac and Vascular Group, showing a 9% increase in net sales, driven by growth across its divisions.
  • 6The Minimally Invasive Therapies Group, significantly bolstered by the Covidien acquisition, reported $9.6 billion in net sales.
  • 7The company continued to execute its share repurchase program, demonstrating a commitment to returning capital to shareholders.

Frequently Asked Questions

The primary driver of Medtronic's performance in fiscal year 2016 was the acquisition of Covidien plc, completed in January 2015. This acquisition significantly expanded the company's size, product offerings, and global footprint, leading to a substantial increase in net sales.

Following the Covidien acquisition, Medtronic reorganized its operations into four primary segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group. This structure aims to better align with its diverse product portfolio and strategic objectives.

Medtronic's strategy revolves around three core pillars: Therapy Innovation, Globalization, and Economic Value. This includes a strong cadence of new product launches, expanding access to healthcare in emerging markets, and focusing on value-based healthcare solutions to improve patient outcomes and reduce costs.

Currency translation had an unfavorable impact of $1.4 billion on net sales in fiscal year 2016 compared to the prior fiscal year, indicating a headwind from foreign currency exchange rate movements.